The regulators approved the vaccine from the pharmaceutical company Shenzhen Kangtai Biological Products, which is currently in the last phase of clinical trials.
Between December, 2020, and May, 2021, the government authorized four vaccines developed by Sinopharm, Sinovac, CanSino and the Institute of Microbiology from the Science Academy, and all are being used in the current vaccination campaign.
China approved the new vaccine amid its fight against the new Covid-19 outbreak in the provinces of Anhui (east) and Liaoning (northeast), with measures such as the designation of several neighborhoods in the medium-risk category, mass health check-ups and disinfection of public places.
Together, specialists from the National Health Commission are investigating the source of transmission of the SARS-CoV-2 coronavirus, which causes the disease. The situation in Anhui and Liaoning broke China’s streak of 20 consecutive days without reporting local Covid-19 cases.